Mawer Investment Management Ltd. Sells 32,387 Shares of Cencora, Inc. $COR

Mawer Investment Management Ltd. trimmed its holdings in Cencora, Inc. (NYSE:COR) by 5.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 618,284 shares of the company’s stock after selling 32,387 shares during the quarter. Cencora comprises about 1.2% of Mawer Investment Management Ltd.’s holdings, making the stock its 24th biggest holding. Mawer Investment Management Ltd.’s holdings in Cencora were worth $208,825,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Oakworth Capital Inc. bought a new position in shares of Cencora in the fourth quarter valued at about $26,000. Elyxium Wealth LLC bought a new position in shares of Cencora in the fourth quarter valued at about $27,000. Archer Investment Corp raised its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the last quarter. Optima Capital LLC bought a new position in shares of Cencora in the fourth quarter valued at about $31,000. Finally, Basepoint Wealth LLC bought a new position in shares of Cencora in the fourth quarter valued at about $32,000. 97.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Robert W. Baird cut their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. William Blair assumed coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Wells Fargo & Company cut their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Finally, Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Price Performance

Shares of COR stock opened at $265.09 on Tuesday. The stock has a 50-day moving average price of $297.22 and a 200 day moving average price of $332.99. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The firm has a market cap of $51.58 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.24 and a beta of 0.59. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Cencora declared that its board has initiated a stock buyback program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.